title: Statement of the AGNP-Work Group "Child and Adolescent Pharmacology" on the decision of the Joint Federal Committee (GBA) of the 17/02/2011 to combine escitalopram with citalopram into a fixed amount group.
authors.affiliation: Kliniken für Kinder- und Jugendpsychiatrie, Psychotherapie und Psychosomatik der Vivantes Netzwerk für Gesundheit GmbH, Klinikum im Friedrichshain und Klinikum Neukölln, Landsberger Allee 49, 10249 Berlin. michael.koelch@vivantes.de
authors.forename: Michael
authors.initials: M
authors.lastname: Kölch
mesh_terms: D000293:Adolescent; D002648:Child; D015283:Citalopram / Q000191:economics* / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D016527:Drug Costs; D005858:Germany; D006801:Humans; D009313:National Health Programs / Q000191:economics*; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D013810:Therapeutic Equivalency
chemical_list: D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors